BC
PMVP icon

Boxer Capital’s PMV Pharmaceuticals PMVP Stock Holding History

Boxer Capital’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,163,795
Closed -$19.4M – 65
2023
Q3 		$19.4M Hold
3,163,795
– – 1.03% 33
2023
Q2 		$19.8M Hold
3,163,795
– – 0.92% 38
2023
Q1 		$15.1M Hold
3,163,795
– – 0.74% 39
2022
Q4 		$27.5M Hold
3,163,795
– – 1.45% 26
2022
Q3 		$37.6M Sell
3,163,795
-334,841
-10% -$4.84M 2.12% 15
2022
Q2 		$49.9M Hold
3,498,636
– – 3.16% 7
2022
Q1 		$72.8M Buy
3,498,636
+660,400
+23% +$11.6M 3.74% 8
2021
Q4 		$65.6M Buy
2,838,236
+570,000
+25% +$13.8M 2.55% 11
2021
Q3 		$67.6M Hold
2,268,236
– – 2.36% 10
2021
Q2 		$77.5M Hold
2,268,236
– – 2.73% 6
2021
Q1 		$74.6M Hold
2,268,236
– – 2.53% 7
2020
Q4 		$140M Hold
2,268,236
– – 4.48% 5
2020
Q3 		$80.5M Buy
+2,268,236
New +$83.5M 2.78% 7

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Boxer Capital's PMVP Position: Q4 2023 in Review

Boxer Capital sold out of PMV Pharmaceuticals (PMVP) in Q4 2023, closing a stake of 3,163,795 shares — an estimated $19.4M sold.

Boxer Capital first reported a position in PMVP in Q3 2020 and held it in 13 quarters. The position peaked at $140M in Q4 2020. 98 funds tracked by Wall St. Rank hold PMVP as of Q4 2023.

  • Boxer Capital reported no remaining PMV Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Boxer Capital sold 3,163,795 PMV Pharmaceuticals shares in Q4 2023, an estimated $19.4M.
  • Boxer Capital first reported a position in PMV Pharmaceuticals in Q3 2020 and held it in 13 quarters.
  • Boxer Capital's PMV Pharmaceuticals position peaked at $140M in Q4 2020.
  • 98 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2023.

Based on Boxer Capital's 13F filing for Q4 2023, filed 14 Feb 2024.